Scarica l'app Stockscreener
3.52
0.86%
0.03
Dopo l'orario di chiusura:
3.49
-0.03
-0.85%
Precedente Chiudi:
$3.49
Aprire:
$3.51
Volume 24 ore:
647.96K
Relative Volume:
0.60
Capitalizzazione di mercato:
$223.73M
Reddito:
$149.50M
Utile/perdita netta:
$-74.62M
Rapporto P/E:
-2.9737
EPS:
-1.1837
Flusso di cassa netto:
$-82.95M
1 W Prestazione:
+2.03%
1M Prestazione:
+17.33%
6M Prestazione:
+108.28%
1 anno Prestazione:
+179.37%
Intervallo 1D:
$3.495
$3.715
Intervallo di 1 settimana:
$3.30
$3.88
Portata 52W:
$1.10
$3.88
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.52 | 221.82M | 149.50M | -74.62M | -82.95M | -1.1837 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
Recap Report: What is the next catalyst for MacroGenics IncQuarterly Profit Report & AI Enhanced Trading Alerts - baoquankhu1.vn
MacroGenics (MGNX) price target increased by 11.11% to 4.08 - MSN
Sentiment Review: Whats the profit margin of MacroGenics Inc2026 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn
B Riley Securities upgrades MacroGenics (MGNX) - MSN
MacroGenics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley Securities | MGNX Stock News - GuruFocus
Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley - GuruFocus
Macrogenics Inc Stock Historical Valuations | HAM:M55 - GuruFocus
Macrogenics Inc Stock Intrinsic Values | HAM:M55 - GuruFocus
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble (MGNX) - Seeking Alpha
B.Riley upgrades MacroGenics stock rating on ADAM9 ADC potential By Investing.com - Investing.com South Africa
B.Riley upgrades MacroGenics stock rating on ADAM9 ADC potential - Investing.com
B. Riley Upgrades MacroGenics to Buy From Neutral, Triples Price Target to $9 From $3 - marketscreener.com
MacroGenics gains removal of FDA partial hold on lead program - MSN
MacroGenics gains removal of FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study - TipRanks
FDA Lifts Partial Clinical Hold on MacroGenics’ LINNET Study for Lorigerlimab in Gynecologic Cancers, Enrollment to Resume - Minichart
MacroGenics resumes enrollment in lorigerlimab cancer study By Investing.com - Investing.com Canada
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study - Bitget
MacroGenics resumes enrollment in lorigerlimab cancer study - Investing.com
FDA Lifts Partial Hold on MacroGenics' (MGNX) LINNET Study - GuruFocus
MacroGenics Resumes LINNET Trial After FDA Hold Lifted - TipRanks
FDA Lifts Partial Clinical Hold on MacroGenics' LINNET Study; Enrollment to Resume - TradingView — Track All Markets
FDA lifts hold on MacroGenics (NASDAQ: MGNX) LINNET gynecologic cancer trial - Stock Titan
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study - The Manila Times
MacroGenics can enroll new cancer patients after FDA lifts study hold - Stock Titan
[DEF 14A] MACROGENICS INC Definitive Proxy Statement - Stock Titan
MacroGenics: Balancing Regulatory Setbacks with Pipeline Promise () - aktiencheck.de
Dip Buying: Can MacroGenics Inc be the next market leader2026 Risk Factors & Short-Term High Return Ideas - baoquankhu1.vn
Volatility Watch: What is the next catalyst for MacroGenics IncWeekly Stock Recap & High Return Trade Opportunity Guides - baoquankhu1.vn
Medtronic Outperforms MacroGenics in Financial Comparison - National Today
MGNX Earnings History & Surprises | EPS & Revenue Results | MACROGENICS INC (NASDAQ:MGNX) - ChartMill
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Brokerages - Defense World
Retail Trends: Can MacroGenics Inc disrupt its industryPortfolio Value Report & Smart Money Movement Alerts - baoquankhu1.vn
Investment Report: Can MacroGenics Inc expand its profit margins2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
Vanguard reports 0 shares in MacroGenics (NASDAQ: MGNX) - Stock Titan
Aug Drivers: How does MacroGenics Inc compare to its peersMarket Activity Recap & Short-Term Swing Trade Alerts - baoquankhu1.vn
MacroGenics Secures Financial Runway Ahead of Pivotal Clinical Milestones () - aktiencheck.de
Treasury Yields: Can MacroGenics Inc disrupt its industry2026 AllTime Highs & Verified High Yield Trade Plans - baoquankhu1.vn
Patterns Watch: What is the next catalyst for MacroGenics IncCEO Change & Fast Exit Strategy with Risk Control - baoquankhu1.vn
VIX Spike: Can MacroGenics Inc be the next market leaderTrade Entry Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Share Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Why is MacroGenics stock sinking Tuesday? - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
Sentiment Review: Will MacroGenics Inc outperform the market in YEAR2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Bull Run: Is MacroGenics Inc attractive for institutional investorsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com Nigeria
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):